« Return to News | Clinical Intelligence

Apogenix receives grant to commence phase II trial

Monday, January 9, 2012 09:32 AM

Apogenix, a biopharmaceutical company based in Heidelberg, Germany, received a $3 million BMBF grant (German Federal Ministry of Education and Research) as partner of the Biotech Cluster Ryine-Neckar. The grant will be used to further advance the company’s lead substance APG101, a fully human protein that aids in treating solid tumors, such as glioblastoma multiforme (GBM).

APG101 is the most advanced inhibitor of the CD95 ligand (CD95L) in clinical development. In September 2011, Apogenix announced the completion of patient recruitment of its phase II clinical trial in GBM, which is now planned for 2013.

"This grant plays a substantial role in the development of our lead substance APG101 for the treatment of life-threatening diseases with a high unmet medical need,” said Dr. Thomas Hoger, CEO/CFO of Apogenix. “This allows us to develop APG101 for MDS. We firmly believe that the therapeutic potential of APG101 goes far beyond the treatment of GBM and that we have a realistic chance to show proof-of-concept in a phase II trial planned for 2013."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.